Indo Us Biotech profitability ratios

Per cent unless marked ×
Tap a line for its trendLast 12Mto Sep 2026FY26Mar 2026FY25Mar 2025
Returns
15.3%15.3%20.7%
11.4%11.4%16.6%
18.4%18.4%21.9%
5.3%12.3%18.9%
Margins
9.0%15.4%18.2%
14.6%14.6%17.2%
—−26.2%—
5.1%12.6%15.9%
4.5%11.9%15.7%
−16.8%−16.8%−1.4%
Additional
12.8%5.7%1.6%
—0.0%3.1%
15.3%15.3%20.1%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

INDOUS₹78.36

Indo Us Biotech Limited

· FMCG & Retail
₹ CrorePeersKOHINOORNATHBIOGENAGRITECHSARVESHWARSUKHJITSREGAALBSHSLGULPOLYMcap ₹157 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/09/2026
Returns
Return on Common Equity20.7215.3415.34
Return on Assets16.6311.3611.36
Return on Capital Employed21.8818.4018.40
Return on Invested Capital18.8512.305.30
Margins
EBITDA Margin18.2315.409.02
Operating Margin17.1814.5914.59
Incremental Operating Margin—-26.17—
Pretax Margin15.9212.605.13
Net Income Margin15.6711.884.47
FCF Margin-1.37-16.75-16.75
Additional
Effective Tax Rate1.595.7312.81
Dvd Payout Ratio3.080.00—
Sustainable Growth Rate20.0815.3415.34
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.